While demethylating agent toxicity are not associated with CBL and SRSF2 mutations [19], higher abundance of TET2 mutations have been previously associated with increased sensitivity to hypomethylating agents in patients with MDS [20]. Here, TET2 is linked to myelodysplastic syndrome.